Literature DB >> 18431556

[Molecular pathologic KRAS mutation analysis. A prerequisite of effective antibody treatment for metastasized colorectal cancer].

M Dietel1, A Tannapfel, G Baretton, H Kreipe, M Kloor, H Gabbert, T Kirchner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18431556     DOI： 10.1007/s00104-008-1514-x

Source DB:  PubMed          Journal:  Chirurg        ISSN： 0009-4722            Impact factor:   0.955


× No keyword cloud information.
  6 in total

1.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

Authors:  W De Roock; H Piessevaux; J De Schutter; M Janssens; G De Hertogh; N Personeni; B Biesmans; J-L Van Laethem; M Peeters; Y Humblet; E Van Cutsem; S Tejpar
Journal:  Ann Oncol       Date:  2007-11-12       Impact factor: 32.976

2.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

3.  Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

Authors:  Josep Tabernero; Eric Van Cutsem; Eduardo Díaz-Rubio; Andrés Cervantes; Yves Humblet; Thierry André; Jean-Luc Van Laethem; Patrick Soulié; Esther Casado; Chris Verslype; Javier Sastre Valera; Giampaolo Tortora; Fortunato Ciardiello; Oliver Kisker; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

4.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Authors:  Silvia Benvenuti; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Carlo Zanon; Mauro Moroni; Silvio Veronese; Salvatore Siena; Alberto Bardelli
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

5.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

6.  Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

Authors:  S Siena; M Peeters; E Van Cutsem; Y Humblet; P Conte; E Bajetta; D Comandini; G Bodoky; G Van Hazel; T Salek; M Wolf; G Devercelli; M Woolley; R G Amado
Journal:  Br J Cancer       Date:  2007-11-27       Impact factor: 7.640
  6 in total
  7 in total

1.  [BRAF mutation detection in metastatic melanoma].

Authors:  M Dietel; A Enk; A Lehmann; J Bauer; C Garbe; U Kellner; T Kirchner; A Jung; H Kreipe; S Merkelbach-Bruse; R Büttner; J Rüschoff; W Schlake; P Schirmacher; R Penzel; R Stadler
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

2.  [Molecular pathology as an necessity: its role in diagnostic and predictive pathology].

Authors:  K W Schmid
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

3.  KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

Authors:  Wilko Weichert; Christiane Schewe; Annika Lehmann; Christine Sers; Carsten Denkert; Jan Budczies; Albrecht Stenzinger; Hans Joos; Olfert Landt; Volker Heiser; Christoph Röcken; Manfred Dietel
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

Review 4.  [Molecular pathology of colorectal cancer].

Authors:  J H L Neumann; A Jung; T Kirchner
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

5.  Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status.

Authors:  Nina Tiemann; Guido Hildebrandt; Katrin Manda
Journal:  Med Oncol       Date:  2011-08-14       Impact factor: 3.064

Review 6.  [Molecular pathogenesis. Its importance in targeted therapy in colorectal cancer].

Authors:  M Kloor; S Michel; M von Knebel Doeberitz
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 7.  The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

Authors:  Sebastian Stintzing; Volker Heinemann; Nicolas Moosmann; Wolfgang Hiddemann; Andreas Jung; Thomas Kirchner
Journal:  Dtsch Arztebl Int       Date:  2009-03-20       Impact factor: 5.594
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.